Omeros Corporation today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback